Recent Finacing
Recent Raise
Incyclix Bio is a next-generation cell cycle control company developing INX-315, a potent and selective CDK2 inhibitor for advanced and resistant cancers.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Incyclix Bio.
